H-CYTE, Inc. (HCYT)
OTCMKTS: HCYT · Delayed Price · USD
2.50
+0.05 (2.04%)
Jun 2, 2023 4:00 PM EDT - Market closed
Company Description
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States.
The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders.
It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
The company is headquartered in Tampa, Florida.
H-CYTE, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Michael W. Yurkowsky |
Contact Details
Address:
2202 N. West Shore Blvd, Ste 200 Tampa, Florida 33607 United States | |
| Phone | 844-633-6839 |
| Website | hcyte.com |
Stock Details
| Ticker Symbol | HCYT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001591165 |
| CUSIP Number | 404124109 |
| ISIN Number | US4041241096 |
| Employer ID | 46-3312262 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael W. Yurkowsky | Chief Executive Officer and Director |
| Jeremy D. Daniel | Chief Financial Officer |
| Dr. Tanya Rhodes Ph.D. | Chief Scientific Officer |
| Jeffery Wright CPA, CPA | Controller and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2023 | 10-Q | Quarterly Report |
| May 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 10, 2023 | 10-K | Annual Report |
| Apr 18, 2023 | 8-K | Current Report |
| Apr 3, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 2, 2023 | 8-K | Current Report |
| Feb 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 28, 2022 | 8-K | Current Report |
| Nov 14, 2022 | 10-Q | Quarterly Report |
| Oct 7, 2022 | 8-K | Current Report |